Nextel Medical Corp. (MAJI) intrinsic value & 10-year financials
Nextel Medical Corp. (MAJI) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue reached to $0, with an average return on invested capital of 837.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.00
- Revenue (FY2020)
- $0
- ROIC (10-yr avg)
- 837.5%
- Free cash flow (FY2020)
- —
MAJI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2020 | $0 | -$435.9K | — | — | — | 155.7% |
| FY2019 | $0 | -$125.2K | — | — | — | 82.5% |
| FY2018 | $0 | -$575 | — | — | — | 0.8% |
| FY2017 | — | — | — | — | — | — |
| FY2012 | $0 | -$6.2M | — | — | — | 4042.3% |
| FY2011 | $0 | -$100.6K | — | — | — | 543.5% |
| FY2010 | — | -$5.7K | — | — | — | 200.0% |
| FY2009 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Nextel Medical Corp. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Nextel Medical Corp. has earned high returns on invested capital, averaging 22.1% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Nextel Medical Corp. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Nextel Medical Corp. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.